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The aim of this multicenter GIMEMA study was to correlate autoimmune complications
(AIC) in B-cell chronic lymphocytic leukemia (B-CLL) with stage and therapy.
Autoimmune hemolytic anemia (129/194 cases) and autoimmune thrombocytopenia
(35/194 cases) were typically present in advanced and multi-treated disease. Age over
the median, stage C and first and second line therapy were identified as independent
risk factors by multivariate analysis. In contrast, non-hematologic AIC (30/194 cases)
and the presence of serological markers of autoimmunity were mostly observed in
early B-CLL, suggesting different pathogenic mechanisms underlying hematologic and
non-hematologic autoimmune phenomena in B-CLL.
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The relationship between B-cell chron-ic lymphocytic leukemia (B-CLL) andthe immune system is widely recog-
nised.1 The disease is characterized by
immunodeficiency, hypogammaglobuline-
mia and a high prevalence of autoimmune
phenomena mainly restricted to blood cell
self-antigens.2,3 Autoimmune hemolytic ane-
mia (AIHA) and thrombocytopenia (AITP)
are known complications of B-CLL, whereas
there are only few reports on other autoim-
mune diseases and on serological markers of
autoimmunity.2-4 The occurrence of autoim-
mune cytopenias was commonly considered
a poor prognostic factor,5 although, more
recently, this has been questioned.6,7 Reports
on other autoimmune phenomena are anec-
dotal.8-10 No studies exist that correlate non-
hematologic autoimmune diseases and the
presence of autoantibodies with the clinical
stage of B-CLL and its therapy. The aim of
this multicenter GIMEMA study was to
determine the presence of different autoim-
mune complications (AIC) in B-CLL (hema-
tologic cytopenias, other autoimmune dis-
eases, and serological markers of autoimmu-
nity) and their relationship with B-CLL stage
and therapy.
Design and Methods
Case series and diagnosis of AIC
The diagnosis and staging of B-CLL were
performed according to the National Cancer
Institute criteria and the Binet staging sys-
tem.11,12 AIC were recorded prospectively
between October 2001 and May 2003 (30
cases), and retrospectively through chart
reviews (164 cases) among all the B-CLL
patients regularly followed (total 3150) by 18
hematology centers of the GIMEMA group.
Age, gender, and B-CLL stage and therapy
were recorded before the occurrence of the
AIC, to avoid confounding AIHA and AITP
on B-CLL stage. First line therapy consisted
of chlorambucil with or without steroids;
second line treatment mostly consisted of
cyclophosphamide with or without an
anthracycline or in fludarabine-based regi-
mens. The diagnosis of AIHA was depend-
ent on the presence of a positive direct
antiglobulin test (DAT), that of AITP was
made according to the British Committee for
Standards in Haematology,13 and the diagno-
sis of other AIC was made according to stan-
dard clinical and immunological criteria.14
The same information collected for the
patients with AIC (age, gender, stage and
therapy) was also recorded for 434 other B-
CLL patients (all the patients of the three
main participating centers because data
were not available for all 3,150), considered
as the control B-CLL group. This study was
performed after obtaining informed consent
from patients and approval from the institu-
tional Human Research Committee. The
procedures followed were in accordance
with the Helsinki international ethical stan-
dards on human experimentation.
Serological markers of autoimmunity
Serological studies were performed in 227
consecutive patients of the 434 B-CLL
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patients without AIC forming the control group. The
following antibodies were detected by standard tech-
niques:15 anti-nuclear (ANA), anti-smooth muscle
(SMA), anti-mitochondrial (AMA), anti-parietal cells
(PCA), and anti-liver-kidney-microsomal antibodies
(LKM) by indirect immunofluorescence on Hep-2; anti-
DNA antibodies by indirect immunofluorescence on
Crithidia luciliae; anti-extractable nuclear antigen (ENA,
in particular, SS-A, SS-B, Sm, RNP, Scl-70), anti-thy-
roglobulin (anti-Tg), anti-thyroid peroxidase (anti-TPO),
anti-neutrophil cytoplasmic (ANCA), anti-cardiolipin
IgG and IgM (ACA), and anti-β-2-glycoprotein 1 IgG
and IgM antibodies (β2GP1) by ELISA; rheumatoid fac-
tor by standard nephelometry.
Statistical analysis
Differences in distribution of stage and treatment
among groups were evaluated using the χ2 test.
Multivariate analyses were performed using a logistic
model. Computations were performed with the SAS
statistical package (8.1 Version, SAS Institute Inc., Cary,
NC, USA). p values lower than 0.05 were considered
statistically significant.
Results ad Discussion
AIC in B-CLL patients
There were 194 cases of AIC. The most frequent form
of AIC was AIHA (129 cases, 66%), followed by AITP (35
cases, 18%), and 30 other autoimmune diseases (16%):
bullous pemphigus (n=9), Hashimoto’s thyroiditis (n=8),
rheumatoid arthritis (n=4), systemic lupus erythematosus
(n=1), autoimmune glomerulonephritis (n=1), autoim-
mune gastritis (n=1), Sjögren’s syndrome (n=1),
polymyositis-dermatomyositis (n=1), vasculitis (n=1),
autoimmune polyneuropathy (n=1), ulcerative colitis
(n=1), and Raynaud’s disease (n=1). As for idiopathic
AIHA, the great majority of cases of B-CLL-associated
AIHA (89%) were due to warm autoantibodies
(IgG+DAT); only 11% were cold hemagglutinin diseases
due to IgM autoantibodies (anti-C’+DAT).
Relationship between AIC and B-CLL stage and
therapy
The statistical analysis was conducted on the 164 retro-
spectively identified cases of AIC. The small group of 30
new cases was considered separately in the statistical
analysis because these differed significantly for clinical
stage and therapy from the retrospective group. By com-
paring patients with and without AIC (Table 1) we found
that the former had a higher median age (p=0.03), were
mostly in advanced disease stage and had already been
treated with first and second line therapy (p<0.001).
Multivariate analysis showed that age >69 years (median
age), stage C and prior administration of first and second
line therapy emerged as independent factors significantly
related with the occurrence of AIC. Considering the rela-
tionship between the different types of AIC and
stage/therapy (Table 2), we found that the majority of
patients with AIHA were in stage C whereas cases of
AITP were equally distributed according to stage and the
Table 1. Clinical data of B-CLL patients with or without autoim-
mune complications (control B-CLL).
Control B-CLL Autoimmune Multivariate
(n=434) complications analysis
(n=164) OR 95%CI
Age (years) 68.3±10.3 70.3±9.6 2.78 1.75-4.43
Gender M/F (%) 239/195 (55/45) 85/79 (52/48) 0.73 0.47-1.13
Stage A (%) 291 (67) 53 (32) 1.00 Ref
Stage B (%) 100 (23) 39 (24) 1.40 0.83-2.37
Stage C (%) 43 (10) 72 (44) 2.87 1.64-5.04
No therapy (%) 272 (63) 11 (7) 1.00 Ref
First line therapy (%) 110 (25) 80 (49) 13.33 6.70-26.51
Second line therapy (%) 52 (12) 73 (44) 27.48 12.77-59.14
Age is given as mean ± SD; OR: odds ratio; CI: confidence intervals.
Table 2. Clinical data of the B-CLL patients with the different
autoimmune complications. Multivariate analysis of 113 patients
with AIHA.
AIHA AITP Other
(n=113) (n=28) autoimmune
complications
(n=23)
OR CL
Age (years) 71.4±9.1 4.85 2.65-8.89 68.4±11.3 67.2±9.2
Gender 60/53 0.75 0.45-1.26 16/12 9/14
M/F (%) (53/47) (57/43) (39/61)
Stage A (%) 26 1.00 Ref 10 17
(23) (36) (74)
Stage B (%) 26 2.12 1.13-4.01 9 4
(23) (32) (17)
Stage C (%) 61 6.54 3.43-12.78 9 2
(54) (32) (9)
No therapy 2 1.00 Ref 0 (0) 9
(%) (2) (39)
First line 58 47.87 11.31- 13 9
therapy (%) (51) 202.68 (46) (39)
Second line 53 99.34 20.57- 15 5
therapy (%) (47) 479.81 (54) (22)
II line-treated 28 91.32 19.28- 0 0
with (25) 432.52 (0) (0)
fludarabine (%)
Age is given as mean ± SD; OR: odds ratio; CL: confidence limits.
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Autoimmunity in B-CLL
other autoimmune diseases were mostly observed in
stage A (p<0.001). As regards chemotherapy, both AIHA
and AITP were almost exclusively observed in patients
with first and second line-treated B-CLL, and the other
autoimmune diseases were equally distributed. We evalu-
ated in particular the relationship between AIHA and sec-
ond line therapy with fludarabine. Fludarabine-treated
patients accounted for 28/53 and 33/52 of those with AIC
and control B-CLL patients, respectively. Multivariate
analysis showed that the relative risk of developing AIHA
was similar in patients treated with second line therapy
with or without fludarabine. As found for all AIC, age
above the median, disease progression (stage B and C) and
therapy intensification (first and second line) emerged as
independent risk factors for AIHA. To minimize the
effects of disease progression on the analysis, we focused
on stage A patients only. Multivariate analysis confirmed
that variables more associated with AIHAwere age above
the median (OR 3.43, CI 1.22-9.63), first line therapy (OR
15.62, CI 5.00-48.82), and second line therapy (OR 48.64,
CI 10.00-239.19).
Prospective study
This group was mainly composed of stage A (54%) and
untreated (67%) patients, beingmore similar to the control
group of B-CLL patients without AIC. For this reason and
because of the small number of cases the distribution of
the different AIC among stages and treatments was not
significant. However, even in this small group, multivari-
ate analysis showed that stage C emerged as an independ-
ent factor significantly related with the occurrence of AIC
(OR 4.78, CI 1.61-14.17).
Follow-up of clinical AIC
Follow-up data were available for 116/194 cases of AIC.
Patients with AIHA, AITP, and the other autoimmune dis-
eases recovered in 65%, 54%, and 40% of cases, respec-
tively. It should be noted that 14/33 (42%) cases of refrac-
tory AIHA were fatal and that death was directly due to
the hemolytic crisis in 5/14.
Prevalence of serological markers of autoimmunity
We found that 93/227 (41%) of B-CLL patients, mostly
in stage A, had at least one positive test for a marker of
autoimmunity, distributed as follows: 36 ANA, 25 ACA,
23 RF, 23 anti-TPO/anti-TG, 20 SMA, and 10 miscella-
neous (AMA, anti-DNA, anti-PCA). Considering all posi-
tive autoimmune phenomena grouped as positive serolog-
ical autoantibodies only, hematologic diseases (AIHA and
AITP), and non-hematologic diseases (Figure 1), there was
a statistically significant distribution with respect to the
clinical stage (p<0.001). In fact, serological and clinical non-
hematologic complications were mostly observed in stage
A patients, whereas more than 70% of hematologic com-
plications were found in patients with advanced disease
(B+C stage).
The results of this study showed that AIC occur in
roughly 5% of patients with B-CLL. The more frequent
complication was AIHA, as already reported,2-4 followed
by AITP and other autoimmune diseases, the latter two
with a similar prevalence. AIC were associated with
advanced and multi-treated disease, as demonstrated by
multivariate analysis, which identified age over the
median, stage C and first and second line therapy as
independent risk factors. This finding is in line with the
recently reported close correlation between ZAP-70
expression and incidence of autoimmune cytopenias in
B-CLL.16Considering only AIHA, the more frequent and
potentially fatal complication, multivariate analysis
gave comparable results, adding stage B to stage C, and
confirming first and second line therapy as independent
risk factors. Also considering stage A patients only, to
avoid the confounding effect of anemia of advanced and
multi-treated disease, variables more associated with
the presence of AIHA were age over the median, and
first line and second line therapy. Interestingly, multi-
variate analysis showed that patients treated with or
without fludarabine have a comparable risk of AIHA, at
variance with the reported association between AIHA
and fludarabine treatment,17,18 but in agreement with
recent observations by Catowsky et al.19
The novel finding of our study is that the distribution
of the different AIC differed with respect to stage and
therapy, in that AIHA and AITP were typically present
in advanced and multi-treated disease, whereas the
non-hematologic autoimmune diseases and serological
markers of autoimmunity were mostly observed in
early B-CLL. Hematologists are usually familiar with
AIHA and AITP, but less so with non-hematologic AIC.
The latter complications, even if usually less severe than
hematologic ones, should be carefully searched for, par-
ticularly in patients with early B-CLL. Although it can-
not be excluded that steroids and cytotoxic drugs may
Figure 1. Distribution of autoimmune phenomena grouped into
hematologic complications (AIHA and AITP, ), non-hematologic
diseases (), and serological autoantibodies only (), χ2 test:
p<0.001.
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successfully treat non-hematologic AIC so that they are
less prominent in more heavily treated patients, this dif-
ferent distribution of complications is open to other
interpretations. Hall et al.20 demonstrated that malignant
B-CLL cells are able to present purified Rh protein to
autoreactive T-helper cells, driving an autoimmune
response against erythrocytes. Autoimmunity against
blood cells might, therefore, reflect a late event in the
natural history of B-CLL, related to the accumulation of
malignant B-CLL antigen-presenting cells. In contrast,
non-hematologic AIC, as well as serological autoimmu-
nity, might have a different pathogenic mechanism,
involving deficient control by normally-competent T
cells, already present in early disease stage.
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